Overview

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess and compare the pharmacokinetic properties of YM178 in normal subjects and those with mild, moderate and severe renal impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Mirabegron